The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 06, 2019

Filed:

Dec. 30, 2015
Applicant:

Korea Research Institute of Chemical Technology, Daejeon, KR;

Inventors:

Jong Yeon Hwang, Jeollabuk-do, KR;

Hyoung Rae Kim, Daejeon, KR;

Jae Du Ha, Daejeon, KR;

Sung Yun Cho, Daejeon, KR;

Hee Jung Jung, Daejeon, KR;

Pilho Kim, Daejeon, KR;

Chang Soo Yun, Daejeon, KR;

Chong Ock Lee, Daejeon, KR;

Chi Hoon Park, Daejeon, KR;

Chong Hak Chae, Daejeon, KR;

Sunjoo Ahn, Daejeon, KR;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/506 (2006.01); C07D 239/30 (2006.01); C07D 239/48 (2006.01); A23L 33/10 (2016.01); A61P 35/00 (2006.01); C07B 43/04 (2006.01); C07C 13/48 (2006.01);
U.S. Cl.
CPC ...
A61K 31/506 (2013.01); A23L 33/10 (2016.08); A61P 35/00 (2018.01); C07B 43/04 (2013.01); C07C 13/48 (2013.01); C07D 239/30 (2013.01); C07D 239/48 (2013.01); C07B 2200/07 (2013.01);
Abstract

The present invention relates to a 4-(2-amino-tetrahydronaphthaleneyl)pyrimidine derivative, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of cancer comprising the same as an active ingredient. The 4-(2-amino-tetrahydronaphthaleneyl)pyrimidine derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention is very effective in suppressing anaplastic lymphoma kinase (ALK) activity and as a result it can improve the effectiveness of treatment on cancer cells having anaplastic lymphoma kinase (ALK) fusion proteins such as EML4-ALK and NPM-ALK, so that it can be effectively used as a pharmaceutical composition for preventing or treating cancer.


Find Patent Forward Citations

Loading…